TG Therapeutics Inc (TGTX) concluded trading on Wednesday at a closing price of $35.85, with 6.4 million shares of worth about $229.42 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 68.23% during that period and on April 09, 2025 the price saw a gain of about 0.90%. Currently the company’s common shares owned by public are about 155.84M shares, out of which, 141.43M shares are available for trading.
Stock saw a price change of -9.97% in past 5 days and over the past one month there was a price change of -4.53%. Year-to-date (YTD), TGTX shares are showing a performance of 19.10% which increased to 139.48% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.93 but also hit the highest price of $43.32 during that period. The average intraday trading volume for TG Therapeutics Inc shares is 2.70 million. The stock is currently trading -9.79% below its 20-day simple moving average (SMA20), while that difference is up 0.93% for SMA50 and it goes to 27.87% higher than SMA200.
TG Therapeutics Inc (NASDAQ: TGTX) currently have 155.84M outstanding shares and institutions hold larger chunk of about 62.26% of that.
The stock has a current market capitalization of $5.63B and its 3Y-monthly beta is at 2.12. PE ratio of stock for trailing 12 months is 256.81, while it has posted earnings per share of $0.14 in the same period. Its PEG reads 1.64 and has Quick Ratio of 5.03 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TGTX, volatility over the week remained 11.51% while standing at 7.16% over the month.
Analysts are in expectations that TG Therapeutics Inc (TGTX) stock would likely to be making an EPS of 0.16 in the current quarter, while forecast for next quarter EPS is 0.34 and it is 1.89 for next year. For the current quarter EPS, analysts have given the company a lowest target 0.12 which is 0.21 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.07 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 545.38% while it is estimated to increase by 99.08% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by TD Cowen on October 29, 2024 offering a Buy rating for the stock and assigned a target price of $50 to it. Coverage by Goldman stated TG Therapeutics Inc (TGTX) stock as a Neutral in their note to investors on August 02, 2023, suggesting a price target of $12 for the stock. On June 26, 2023, Jefferies Resumed their recommendations, while on May 20, 2022, BofA Securities Initiated their ratings for the stock with a price target of $5. Stock get a Buy rating from B. Riley Securities on February 23, 2022.
